2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1287

Strong Impact of Dysfunctional Variants of ABCG2 on Hyperuricemia and Gout in Children and Adolescents

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1054

Study of the Metabolic Effect of MSCs on Their Chondroprotective and Regenerative Properties: Modulating Their Metabolism to Improve Their Therapeutic Potential for the Treatment of Osteoarthritis

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1650

Subclinical Atheromatosis and Estimation of Cardiovascular Risk in Patients with Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1770

Subglottic Stenosis and Endobronchial Disease in Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 1385

Subjective Well-Being Among Rheumatoid Arthritis Patients

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1222

Suboptimal Immunization Coverage Among Rheumatology Patients in Routine Clinical Care

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1212

Superiority of Musculoskeletal Ultrasound (MSUS) over Clinical Examination Regarding Detection of Arthritis in Patients with Systemic Sclerosis

Imaging of Rheumatic Diseases Poster II: Ultrasound

9:00AM-11:00AM: Abstract Number: 1000

Surface Adenosine Monophosphate Deaminase 2 As a Novel Regulator Modifying Ectonucleotidase-Driven Generation of Anti-Inflammatory Extracellular Adenosine

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1485

Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1659

Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1172

Symptoms Compatible with Osteoarthritis and Self-Reported Osteoarthritis in the Population: Findings from the Canadian Longitudinal Study on Aging

Epidemiology and Public Health Poster II – ARHP

9:00AM-11:00AM: Abstract Number: 1218

Synovial Fluid Culture: Comparison of Two Culture Methods

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1232

Synovial Fluid Profile in Neutropenic Patients with Septic Arthritis

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1053

Synovial Inflammation Identifies Patients Clusters in Osteoarthritis

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1506

Synovial Tissue Histopathology Findings in EARLY RA. Is It Usefull? Analysis of the Belgian CAP48 Cohort

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].